Encompass Health Co. (NYSE:EHC) Shares Sold by JPMorgan Chase & Co.

JPMorgan Chase & Co. trimmed its position in Encompass Health Co. (NYSE:EHC - Free Report) by 15.4% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 1,891,721 shares of the company's stock after selling 343,062 shares during the quarter. JPMorgan Chase & Co. owned about 1.88% of Encompass Health worth $182,816,000 at the end of the most recent reporting period.

Other hedge funds also recently made changes to their positions in the company. UMB Bank n.a. lifted its position in Encompass Health by 387.7% during the third quarter. UMB Bank n.a. now owns 317 shares of the company's stock valued at $31,000 after purchasing an additional 252 shares during the last quarter. V Square Quantitative Management LLC raised its position in shares of Encompass Health by 53.0% during the 3rd quarter. V Square Quantitative Management LLC now owns 404 shares of the company's stock valued at $39,000 after buying an additional 140 shares in the last quarter. Avior Wealth Management LLC bought a new position in shares of Encompass Health in the 3rd quarter valued at about $40,000. Benjamin F. Edwards & Company Inc. grew its position in Encompass Health by 58.9% in the second quarter. Benjamin F. Edwards & Company Inc. now owns 534 shares of the company's stock worth $46,000 after acquiring an additional 198 shares in the last quarter. Finally, Point72 Asia Singapore Pte. Ltd. bought a new stake in Encompass Health during the second quarter worth approximately $58,000. 97.25% of the stock is currently owned by hedge funds and other institutional investors.

Encompass Health Stock Down 0.1 %

Encompass Health stock traded down $0.07 during trading hours on Wednesday, reaching $92.35. The stock had a trading volume of 518,352 shares, compared to its average volume of 638,437. Encompass Health Co. has a 52 week low of $65.99 and a 52 week high of $104.55. The company has a market cap of $9.30 billion, a price-to-earnings ratio of 22.31, a PEG ratio of 1.30 and a beta of 0.86. The company has a debt-to-equity ratio of 0.88, a current ratio of 1.04 and a quick ratio of 1.04. The business's 50 day moving average price is $99.07 and its 200-day moving average price is $93.39.

Encompass Health (NYSE:EHC - Get Free Report) last announced its quarterly earnings data on Monday, October 28th. The company reported $1.03 earnings per share for the quarter, beating analysts' consensus estimates of $0.94 by $0.09. The firm had revenue of $1.35 billion for the quarter, compared to analyst estimates of $1.33 billion. Encompass Health had a net margin of 8.10% and a return on equity of 17.60%. The business's quarterly revenue was up 11.9% compared to the same quarter last year. During the same period in the previous year, the company earned $0.86 earnings per share. Sell-side analysts anticipate that Encompass Health Co. will post 4.29 EPS for the current year.

Encompass Health Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, January 15th. Shareholders of record on Thursday, January 2nd will be given a $0.17 dividend. The ex-dividend date is Thursday, January 2nd. This represents a $0.68 annualized dividend and a yield of 0.74%. Encompass Health's dividend payout ratio is presently 16.43%.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently weighed in on the stock. Royal Bank of Canada increased their target price on shares of Encompass Health from $105.00 to $110.00 and gave the company an "outperform" rating in a research note on Wednesday, October 30th. KeyCorp raised their price objective on shares of Encompass Health from $115.00 to $117.00 and gave the stock an "overweight" rating in a research note on Tuesday, October 29th. UBS Group boosted their target price on Encompass Health from $100.00 to $110.00 and gave the company a "buy" rating in a research report on Wednesday, September 25th. Barclays increased their price target on Encompass Health from $109.00 to $116.00 and gave the stock an "overweight" rating in a report on Tuesday, October 29th. Finally, Truist Financial restated a "buy" rating and set a $116.00 price objective (up previously from $108.00) on shares of Encompass Health in a report on Wednesday, October 30th. Nine investment analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company's stock. According to data from MarketBeat.com, the stock has an average rating of "Buy" and an average target price of $107.11.

About Encompass Health

Encompass Health Corporation provides post-acute healthcare services in the United States and Puerto Rico. It owns and operates inpatient rehabilitation hospitals that provide medical, nursing, therapy, and ancillary services. The company provides specialized rehabilitative treatment on an inpatient basis to patients who have experienced physical or cognitive disabilities or injuries due to medical conditions, such as strokes, hip fractures, and various debilitating neurological conditions.